| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H28N6O5S |
| Molecular Weight | 536.603 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1OC)C(=O)C2=CC=C(C=C2N3C=NC=N3)C4=CSC(NC(=O)[C@@H](N)C(C)C)=N4
InChI
InChIKey=UKKRUIXIDCWALA-QFIPXVFZSA-N
InChI=1S/C26H28N6O5S/c1-14(2)22(27)25(34)31-26-30-18(11-38-26)15-6-7-17(19(8-15)32-13-28-12-29-32)23(33)16-9-20(35-3)24(37-5)21(10-16)36-4/h6-14,22H,27H2,1-5H3,(H,30,31,34)/t22-/m0/s1
| Molecular Formula | C26H28N6O5S |
| Molecular Weight | 536.603 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CKD-516 is a prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting, and antineoplastic activity. Upon administration, tubulin polymerization inhibitor CKD-516 is converted into its active metabolite S-516, which binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. CKD-516 is developed by a Korean company Chong Kun Dang Pharmaceutical Corp. and is investigated in a phase 1/2a clinical trial for the treatment of colorectal cancer in combination with Irinotecan.
